© 2017 ILEX PUBLISHING HOUSE, Bucharest, Roumania
http://www.jrdiabet.ro
Rom J Diabetes Nutr Metab Dis. 24(4):377-384
doi: 10.1515/rjdnmd-2017-0044
INSULIN AND THE BRAIN
Cristina Grosu 1,2, Andrei Cătălin Oprescu 1,3, , Otilia Niţă 1,3, Walther Bild 1,4
1
2
3
4
“Grigore T. Popa” University of Medicine and Pharmacy Iasi, Romania
Department of Neurology, Clinical Rehabilitation Hospital Iasi, Romania
Department of Diabetes, Nutrition and Metabolic Diseases, “Sf Spiridon” Clinical
Emergency Hospital Iasi, Romania
Department of Normal and Pathologic Physiology
received:
October 11, 2017
accepted:
November 27, 2017
available online:
December 15, 2017
Abstract
The brain represents an important site for the action of insulin. Besides the traditionally
known importance in glucoregulation, insulin has significant neurotrophic properties and
influences the brain activity: insulin influences eating behavior, regulates the storage of
energy and several aspects concerning memory and knowledge. Insulin resistance and
hyperinsulinism could be associated with brain aging, vascular and metabolic
pathologies. Elucidating the pathways and metabolism of brain insulin could have a
major impact on future targeted therapies.
key words: insulin, brain, aging, metabolism.
pancreatic beta cells, insulin then penetrates the
Introduction
blood brain barrier (BBB) by means of a carrier,
The brain as an organ is dependent on and influences in the CNS the feeding and
insulin [1]. Receptors for insulin and insulin cognition processes.
itself can be found both in the brain and the
Cerebral metabolism of glucose
choroid
plexus.
After
its
peripheral
Intuitively, the main mechanism through
administration, insulin has been identified in the
cerebrospinal fluid (CSF). In addition, there is which insulin modulates neuronal functions is by
thorough documentation on the role of insulin on regulating glucose metabolism. The uptake of
energy metabolism after its intracere- fuel, mainly glucose, from the cerebral blood
broventricular (ICV) administration. These data vessels initiates the energy metabolism of the
prove that the brain is an important site for the brain. Brain accounts for 25% of total glucose
action of insulin where the peripheral signals are consumption. Alternative substrates are ketone
integrated by means of vast interactions of bodies, fatty acids, lactate and pyruvate, and
neuropeptides
and
hypothalamic
neuro- rarely amino acids. Once inside the cell, glucose
transmitters with the aim of controlling is irreversibly transformed into glucose-6homeostasis [2]. Insulin also has particular roles phosphate (G6P) by hexokinase (HK). In
within the central nervous system (CNS). Being neurons, each G6P molecule is oxidized by
secreted almost entirely in periphery by the glycolysis, oxidative phosphorylation, the
Bdul Independentei nr.1, Iasi, Romania; corresponding author e-mail: andreicatalinoprescu@yahoo.com
tricarboxylic acid cycle (TCA) and the pathway
of pentose phosphate (PPP), producing carbon
dioxide, water and up to 36 adenosine
triphosphate molecules (ATP) [3]. The
contribution of glycolysis to oxidative
phosphorylation for the total amount of ATP
varies in different cells, growth and micromedia. In addition to ATP production, glucose is
used to produce glycogen in astrocytes, pentoses
for nucleotide synthesis and to generate
intermediate metabolites required for lipid
synthesis in the membranes and myelin
structures, and amino acids in the structure of
proteins and neurotransmitters.
The metabolic pathway of glucose in the
brain depends on the type of cell and the
selective expression of the enzymes involved.
Neurons predominantly have an oxidative
metabolism, whereas astrocytes are largely
glycolic [4]. Following cytosolic reactions,
energy fuels are mainly metabolised in the
mitochondria. Pyruvate metabolised glucose can
be actively transported into the mitochondria
where it is converted to acetyl coenzyme A,
which in turn is complexed with citrate produces
nicotinamide adenine dinucleotides (NADH) and
flavin adenine dinucleotides (FADH2) [5]. In
order to maintain an effective and prompt
mitochondrial network, the cell has adaptive
control mechanisms for environmental changes
[6]. Glycolysis and oxidative phosphorylation
are closely coupled and serve as a molecular
interconversion system. The balance between
glycolysis and PPP rates in neurons is very
important. Thus, misappropriation of glucose
utilization exclusively to glycolysis may result in
decreased NADPH availability, increased
oxidative stress and cell death. Though
negligible compared to peripheral energy
deposits, glycogen is the largest energy reserve
in the brain [4]. Astrocyte use of glucose is
complementary to that of neurons.
378
There are two enzymes primarily involved in
the metabolism of glycogen, one being glycogen
synthase (GS) and the other glycogen
phosphorylase (GP). Glycogen, a glycolic
product, is stored exclusively in astrocytes
because GS is in an inactive state in the neurons.
Lactate is formed from glucose in the astrocytes
and then transferred to the neurons, where it is
vital not only for the metabolism of neurons, but
also in creating synapses and dendrites and in
expressing genes involved in the memory
processes.
Deterioration of energy metabolism is
characteristic to brain aging, and to Alzheimer's
disease (AD) and other neurodegenerative
diseases. Both age, and the decreased
metabolism state found in these diseases share
common risk for oxidative stress and
neuroinflammation. The cognitive decline
associated with age could be explained by the
activation of microglia and higher expression of
cytokines involved in inflammation. Also, age
and AD could also have in common an impaired
neurovascular activity mediated by nitric oxide
(NO), leading to progression of neuronal
dysfunction [7].
Insulin receptor and insulin
resistance in the brain
The insulin receptor (IR) belongs to the
family of protein kinase receptors. Studies in
recent decades have confirmed the existence of
insulin and IR in the brain and have
demonstrated the role of insulin-dependent brain
regulation in maintaining balanced body energy.
The presence of cerebral IR has been proved in
animal and human neurons, but also in glial
cells. It has been shown that the structure of
these central receptors and their mechanism of
action is similar to peripheral insulin receptors.
They have a tetramer structure, composed of
four subunits: two alpha and two beta. After
coupling with insulin, the tyrosine kinase is
Romanian Journal of Diabetes Nutrition & Metabolic Diseases / Vol. 24 / no. 4 / 2017
activated and initiates a cascade of intracellular
events similar to those observed in the periphery
[8]. However, there are differences between the
brain and peripheral IR, regarding molecular
size, capacity to determine an immune response,
and the way they are regulated by insulin [9].
Whereas peripheral IR show down-regulation to
excess insulin, the brain IR do not, suggesting
different mechanisms of regulation of the IR in
the two sites. There are also differences in the
concentration of cerebral IR in particular regions
of the brain: the olfactory bulb, vascular plexus,
hypothalamus (especially arcuate nucleus),
limbic system, cerebellum, brain stem,
mesencephalic structures, thalamus are the sites
with most abundant in IR [10]. The presence of
insulin and a high concentration of IRs have
been observed in the hippocampus, a cerebral
structure responsible for cognitive function,
memory and learning ability (including memoryassociated signals) [11]. By acting through
specific receptors, cerebral insulin signaling is
involved in regulating vital processes
responsible for the smooth functioning of the
CNS, not only for the metabolism of "brain"
glucose [12]. Insulin exerts its effects by
allowing control or as a mediator of several
processes such as: cognitive and reproductive
function, energy and weight homeostasis,
neurotransmitters release, synaptic plasticity,
growth, differentiation and function of neurons
[8].
Insulin resistance implies a decreased ability
of insulin to act on the targeted tissues.
Accumulated evidence suggests that cerebral
insulin resistance and decreased glucose
hypometabolism at this site could be the cause,
rather than the consequence of age-related or
disease related neurodegeneration. CNS has an
important contribution in the development of
insulin resistance, obesity and type 2 diabetes
mellitus (T2DM). Impaired central insulin
signaling leads to hyperinsulinemia, decreased
insulin sensitivity and body mass gain. Post
mortem, in people with T2DM or obesity,
reduced expression of neuronal insulin receptors,
along with lower levels of insulin have been
reported [13]. Traditionally, it is understood that
the bond between insulin and its dimerized
receptors activate specific transport proteins that
in turn mediate the facilitated glucose uptake.
However, neurons have the ability to uptake
glucose by other mechanisms as well, including
non-insulin-dependent transporters [12]. Because
most of the cerebral absorption of glucose is not
insulin dependent, the brain has long been
considered insensitive to insulin.
However, the presence and activity of
glucose transporter GLUT4 (which is insulinsensitive) have been demonstrated in several
nuclei. GLUT3 is the most abundant transporter
of glucose in neurons. Glial and endothelial cells
of the brain depend on GLUT1 activity for
interstitial fluid (ISF) and plasma glucose
absorption [14]. Since GLUT1 or GLUT3 are
not insulin-sensitive transporters, most of the
transport of glucose in brain cells does not
require insulin signaling. Still, the brain as an
organ has been proved to be receptive to insulin,
which in particular acts as a neuroregulratory
peptide [1]. GLUT4 has been found together
with IR in the brain and also have been proven to
decrease after T2DM has been induced.
Cognitive processes are vitally regulated by the
uptake of glucose in the brain, and particularly in
the hippocampus, which is why insulin signaling
leads to translation of GLUT4 to the cell
membrane of neurons in the hippocampus.
Studies have shown that administration of
insulin in the hippocampus leads to a fast and
steady rise in local glycolysis in normal animals,
but not in animals with induced T2DM [15]. In
studies showing memory enhancement, insulin
has a dose-response curve with an inverse U
Romanian Journal of Diabetes Nutrition & Metabolic Diseases / Vol. 24 / no. 4 / 2017
379
shape like that noticed when glucose is directly
delivered [11]. The two main sites where insulin
plays a role in neural metabolism by promoting
the absorption of glucose are the hippocampus
and the medial temporal lobe. These data offer
an explanation for the role of insulin in the
cognitive processes in the hippocampus and
create a starting point when addressing the
cognitive decline noticed in diabetes [15].
Administration of insulin into cerebral ventricles
significantly decreases the intake of food and
reduced weight in primates, while also
increasing cognitive function in rats [16,17]. In
humans, the hyperinsulinemic euglycemic clamp
was not found to have an effect on the food
intake in the short-term [18]. Because basal
plasma insulin level correlates with adiposity, it
has been argued that insulin provides CNS with
a regulating or reporting signal regarding energy
reserves, and, even more, a satiety signal [19].
The roles of peripheral insulin
on the brain
The intranasal administration of insulin
facilitates its penetration into cerebrospinal fluid
(CSF) more than the subcutaneous or
intravenous injections. It induces a reduction of
food intake in men, less desire for tasty foods in
women, with no risk of hypoglycemia, and
improved memory in the elderly with cognitive
impairment [20-22]. Many studies have used
CSF as a surrogate for brain interstitial fluid
(ISF). However, recent findings acknowledge
differences in the CSF composition compared
with ISF, when CSF is assessed directly (in the
cerebral ventricles or in the lumbar spine). CSF
is a contributor to the cerebral ISF, but there are
also other solutes carried through the BBB
which create a different composition. The
relative contribution of each of these two
pathways makes it difficult to know the
percentage of peripheral insulin found in ISF.
Animal and human studies consistently show a
380
high gradient of plasma insulin to insulin in CSF
in healthy subjects; plasma insulin is increased
up to 10 or 20 times in those with insulin
resistance [23,24]. This gradient is even greater
in obese people [25].
The consensus is that insulin is produced in
the CNS in little or no amount [26]. Therefore,
insulin from the CNS essentially depends on the
peripheral insulin capacity to cross the BBB. The
role of BBB is to restrict the passage of proteins
and peptides between the two compartments and
is an important interface in the mediation of
intestinal-brain axes. However, there are
peptides and regulatory proteins that pass
through the BBB using either saturable or
unsaturable mechanisms. The hormones insulin
and leptin have specific carriers for passing the
BBB, and the mechanism used by insulin is
saturable. The conveyor is unevenly distributed
in the CNS. Being partially saturated in
euglycemia implies that the main function of
signaling takes place at normal blood levels, and
it’s not to prevent hypoglycaemic events [27].
The insulin transporter through BBB might exist
in order to facilitate the role of insulin in the
CNS as a regulatory peptide [28]. A number of
conditions, such as growth and development, but
also fasting, hibernation, obesity and diabetes,
AD are characterized by a modified insulin
transport rate through the BBB carrier.
Administrating lipopolysaccharides to mice
increases insulin transport through BBB
approximately
three-fold,
indicating
a
mechanism that would promote insulin
resistance in sepsis. Dexamethasone inhibits the
transport of insulin through the BBB which
could explain the improved appetite noticed
during treatment with corticosteroids [29].
Endothelial cells of the brain (BEC) found in
the BBB produce different substances, among
which cytokines, different for each part of the
barrier. As such, adiponectin apparently inhibits
Romanian Journal of Diabetes Nutrition & Metabolic Diseases / Vol. 24 / no. 4 / 2017
the production of interleukin-6 from BEC.
Insulin itself influences BBB, altering its roles in
transport and as enzyme system (e.g. in BEC).
The integrity of the BBB and its capacity to
transport insulin is maintained by the pericytes,
which are pluripotent cells in close contact with
BEC [30,31].
Long-term hyperinsulinism exacerbates the
chronic inflammatory response and increases
oxidative stress. The explanation would be the
intervention of ceramide resulting from
alteration of peripheral lipid metabolism ("liverbrain axis") that passes the BBB with neurotoxic
effects through proinflammatory cytokines [32].
Insulin acts in the CNS mainly as a metabolic
regulatory hormone, where its actions are
mediated by the phosphoinositide-3 kinase
(PI3)/Akt pathway and the Ras/mitogen
activated kinase (MAPK) cascade. The literature
has focused on PI3K as a peripheral and central
insulin-like signaling pathway, including in the
hippocampus. However, there are other
important mechanisms like opening the
potassium ATP channel (KATP), thus modulating
the neural metabolism. Animal studies on insulin
resistance have shown that modulation of KATP
channels in the hippocampus affects memory
performance, proving the ability of insulin to
interfere with activity in this area and through
pathways independent of PI3K interaction.
Significant evidence indicates that the role of
insulin in the brain involves also MAPK [33].
Insulin may also modify synaptic plasticity,
meaning long-term membrane potential (LTP)
and long-term membrane depression (LTD). In
the first situation, insulin acts on the synaptic
membrane by removing AMPA channels or on
the LTP induction by modifying the stimulationresponse frequency curve. Insulin is probably
directly responsible for acute neurotransmission
(both excitatory and inhibitory), and for the
long-term plasticity through GABA-ergic
modulation (GABA receptors are translocated to
the plasma membrane). Several studies propose
that systemic insulin resistance associates itself
with central resistance to insulin and that a cause
for cognitive decline is impaired insulin
signaling. T2DM characterized by insulin
resistance is associated with mnestic disorders
and blockage of insulin signaling in the
hippocampus, producing major cognitive deficits
in these patients [15].
Insulin signaling induces the uptake of
glucose in the brain but also the production of
the insulin degradation enzyme (IDE) as to
prevent hypoglycaemia. IDE degrades both
insulin and beta-amyloid (Aβ), which is why in
hyperinsulinemia, insulin could compete with
Aβ for degradation, leading to Aβ accumulation
[34,35]. Insulin protects neurons against
oxidative stress, associated with conditions such
as diabetes mellitus, chronic ischemia or agerelated neurodegenerative diseases. Oxidative
stress results in insulin stimulating the uptake of
glucose into neurons where it is metabolized into
pyruvate; this restores the intracellular ATP and
phosphocreatine [36]. Insulin also influences the
concentration of adenosine (increasing it inside
the cell, decreasing it outside the cell) using the
PI3 kinase pathway and the one involving
extracellular signal-regulated kinase [37].
There are two theories which confirm the
link between T2DM and AD, even if the subject
is still under debate: insulin resistance and
inflammatory signaling pathways [38]. Insulin
resistance and hyperinsulinemia, which by all
classifications define T2DM, have also been
linked to cognitive impairment in the elderly
[39,40]. While acute insulin administration may
improve some areas of memory, chronic insulin
administration could be linked to memory
impairment [38].
Age-related cognitive decline is linked to the
activation of microglia and increased
Romanian Journal of Diabetes Nutrition & Metabolic Diseases / Vol. 24 / no. 4 / 2017
381
inflammatory cytokines [41]. There is a theory
(still in need for confirmation) which stipulates
that the first modification leading to cognitive
impairment in aging and AD is metabolic
deficiency resulting in dysfunction of the
mitochondria or neuroinflammation resulting in
the activation of microglia and increasing
cytokines. The impairment of mitochondria and
chronic inflammation stimulate each other in a
metabolic-inflammatory axis in both T2DM and
AD [42]. Proinflammatory cytokines are viewed
as an indirect sign of the immunological
impairment which can result in insulin resistance
[43]. Several studies on animals and humans
have shown the anti-inflammatory properties of
insulin which is able to suppress pro-
inflammatory cytokines and to induce antiinflammatory mediators [44].
Conclusions
The deterioration of energy metabolism
characterizes brain aging but also many
neurodegenerative diseases such as AD, but is
also related to other severe mental illnesses. The
decreased brain metabolism found in aged
populations or some diseases is most often
related to selective brain insulin resistance,
microglia activation and neuroinflammation. We
can assert that insulin is a neuroprotective factor
against hypometabolism, oxidative stress,
inflammation
and
apoptosis,
with
neuromodulatory and neurotrophic effects.
REFERENCES
1. Ghasemi R, Haeri A, Dargahi L, Mohamed Z,
Ahmadiani A. Insulin in the brain: sources, localization
and functions. Mol Neurobiol 47: 145-171, 2013.
8. Brüning JC, Gautam D, Burks DJ et al. Role of
brain insulin receptor in control of body weight and
reproduction. Science 289: 2122-2125, 2000.
2. Kleinridders A, Ferris HA, Cai W, Kahn CR.
Insulin action in the brain regulates systemic metabolism
and brain function. Diabetes 63: 2232-2243, 2014.
9. Heidenreich KA, Zahniser NR, Berhanu P,
Brandenburg D, Olefsky JM. Structural differences
between insulin receptors in the brain and peripheral target
tissues. J Biol Chem 258: 8527-8530, 1983.
3. Yin F, Boveris A, Cadenas E. Mitochondrial
energy metabolism and redox signaling in brain aging and
neurodegeneration. Antioxid, Redox Signal 20: 353-371,
2014.
4. Camandola S, Mattson MP. Brain metabolism
in health, aging, and neurodegeneration. EMBO J 36:
1474–1492, 2017.
5. Wang Y, Brinton RD. Triad of risk for late
onset, Alzheimer's: mitochondrial haplotype, APOE
genotype and chromosomal sex. Front Aging Neurosci 8:
232, 2016.
6. Yin F, Cadenas E. Mitochondria: the cellular hub
of the dynamic coordinated network. Antioxid Redox
Signal 22: 961-964, 2015.
7. Lourenço CF, Ledo A, Dias C, Barbosa RM,
Laranjinha J. Neurovascular and neurometabolic
derailment in aging and Alzheimer's disease. Front Aging
Neurosci 7: 103, 2015.
382
10. Schulingkamp RJ, Pagano TC, Hung D, Raffa
RB. Insulin receptors and insulin action in the brain:
review and clinical implications. Neurosci Biobehav Rev
24: 855-872, 2000.
11. McNay EC, Ong CT, McCrimmon RJ,
Cresswell J, Bogan JS, Sherwin RS. Hippocampal
memory processes are modulated by insulin and high-fat
induced insulin resistance. Neurobiol Learn Mem 93: 546553, 2010.
12. Laron Z. Insulin and the brain. Arch Physiol
Biochem 115: 112-116, 2009.
13. Pagotto U. Where does insulin resistance start?
The brain. Diabetes Care 32[Suppl 2]: S174-S177, 2009.
14. McEwen BS, Reagan LP. Glucose transporter
expression in the central nervous system: relationship to
synaptic function. Eur J Pharmacol 490: 13-24, 2004.
15. McNay EC, Recknagel AK. Brain insulin
signaling: a key component of cognitive processes and a
Romanian Journal of Diabetes Nutrition & Metabolic Diseases / Vol. 24 / no. 4 / 2017
potential basis for cognitive impairment in type 2 diabetes.
Neurobiol Learn Mem 96: 432-442, 2011.
streptozotocin-induced diabetic rats. Diabetologia 45:
1017-1025, 2002.
16. Woods SC, Lotter EC, McKay LD, Porte D Jr.
Chronic intracerebroventricular infusion of insulin reduces
food intake and body weight of baboons. Nature 282: 503505, 1979.
28. Banks WA. The blood-brain barrier as a
regulatory interface in the gut-brain axes. Physiol Behav
89: 472-476, 2006.
17. Haj-ali V, Mohaddes G, Babri SH.
Intracerebroventricular insulin improves spatial learning
and memory in male Wistar rats. Behav Neurosci 123:
1309-1314, 2009.
18. Chapman IM, Goble EA, Wittert GA, Morley
JE, Horowitz M. Effect of intravenous glucose and
euglycemic insulin infusions on short-term appetite and
food intake. Am J Physiol 274: R596-R603, 1998.
19. Scherer T, O'Hare J, Diggs-Andrews K et al.
Brain insulin controls adipose tissue lipolysis and
lipogenesis. Cell Metab 13: 183-194, 2011.
20. Benedict C, Kern W, Schultes B, Born J,
Hallschmid M. Differential sensitivity of men and women
to anorexigenic and memory-improving effects of
intranasal insulin. J Clin Endocrinol Metab 93: 13391344, 2008.
21. Hallschmid M, Higgs S, Thienel M, Ott V,
Lehnert H. Postprandial administration of intranasal
insulin intensifies satiety and reduces intake of palatable
snacks in women. Diabetes 61: 782-789, 2012.
22. Reger MA, Watson GS, Green PS et al.
Intranasal
insulin
administration
dose-dependent
modulates vertebral memory and plasma amyloid-beta in
memory-impaired older adults. J Alzheimers Dis 13: 323331, 2008.
23. Strubbe JH, Porte D, Jr, Woods SC. Insulin
responses and glucose levels in plasma and cerebrospinal
fluid during fasting and refeeding in the rat. Physiol Behav
44: 205-208, 1988.
24. Wallum BJ, Taborsky GJ Jr, Porte D Jr et al.
Cerebrospinal fluid insulin levels increase during
intravenous insulin infusions in man. J Clin Endocrinol
Metab 64: 190–194, 1987.
25. Kern W, Benedict C, Schultes B et al. Low
cerebrospinal fluid insulin levels in obese humans.
Diabetologia 49: 2790-2792, 2006.
26. Banks WA. The source of cerebral insulin. Eur J
Pharmacol 490: 5-12, 2004.
29. Banks WA, Gray AM, Erickson MA et al.
Lipopolysaccharide - induced blood-brain barrier
disruption: role of cyclooxygenase, oxidative stress,
neuroinflammation, and elements of the neurovascular
unit. J Neuroinflammation 12: 223, 2015.
30. Xaio H, Banks WA, Niehoff ML, Morley JE.
Effect of LPS on the permeability of the blood-brain
barrier to insulin. Brain Res 896: 36-42, 2001.
31. Banks WA, Owen JB, Erickson MA. Insulin in
the brain: there and back again. Pharmacol Ther 136: 8293, 2012.
32. Jazvinšćak Jembrek M, Hof PR, Simic G.
Ceramides in Alzheimer's disease: key mediators of
neuronal apoptosis induced by oxidative stress and Aβ
accumulation. Oxid Med Cell Longev 2015: 346783, 2015.
33. Zhu X, Lee HG, Raina AK, Perry G, Smith
MA. The role of mitogen-activated protein kinase
pathways in Alzheimer's disease. Neurosignals 11: 270281, 2002.
34. Edland
SD.
Insulin-degrading
enzymes,
apolipoprotein E, and Alzheimer's disease. J Mol Neurosci
23: 213-217, 2004.
35. Li L, Holscher C. Common pathological
processes in Alzheimer's disease and type 2 diabetes: a
review. Brain Res Rev 56: 384-402, 2007.
36. Gray SM, Meijer RI, Barrett EJ. Insulin
regulates brain function, but how does it get there?
Diabetes 63: 3992-3997, 2014.
37. Duarte AI, Proença T, Oliveira CR, Santos
MS, Rego AC. Insulin restores metabolic function in
cultured cortical neurons subjected to oxidative stress.
Diabetes 55: 2863-2870, 2006.
38. Mittal K, Katare DP. Shared links between type
2 diabetes mellitus and Alzheimer's disease: a review.
Diabetes Metab Synd 10[2 Suppl 1]: S144-S149, 2016.
39. Zhong Y, Miao Y, Jia WP, Yan H, Wang BY,
Jin J. Hyperinsulinemia, insulin resistance and cognitive
decline in the older cohort. Biomed Environ Sci 25: 8-14,
2012.
27. Bouchard P, Ghitescu LD, Bendayan M.
Morpho-functional studies of the blood-brain barrier in
Romanian Journal of Diabetes Nutrition & Metabolic Diseases / Vol. 24 / no. 4 / 2017
383
40. Bala C, Niță C, Hâncu N. Severe mental
illnesses and metabolic syndrome: the need for more
awarness and better care. Rom J Diabetes Nutr Metab Dis
23: 7-12, 2016.
41. Popescu CD, Graur M, Grosu C, Ignat BE,
Alexa D. Insulin, the brain and diabetes complications. In:
Diabetes complications. New explanations and solutions
Cheta D (ed). Agir Publishing House, pp 180-206, 2016.
Alzheimer's disease. Free Radic Biol Med 100: 108-122,
2016.
43. Patel PS, Buras ED, Balasubramanyam A. The
role of the immune system in obesity and insulin
resistance. J Obes 2013: 616193, 2013.
44. Sun Q, Li J, Gao F. New insights into insulin:
The anti-inflammatory effect and its clinical relevance.
World J Diabetes 5: 89-96, 2014.
42. Yin F, Sancheti H, Patil I, Cadenas M. Energy
metabolism and inflammation in brain aging and
384
Romanian Journal of Diabetes Nutrition & Metabolic Diseases / Vol. 24 / no. 4 / 2017